Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PTCT | US
-1.33
-3.65%
Healthcare
Biotechnology
30/06/2024
04/10/2024
35.10
35.87
36.28
34.77
PTC Therapeutics Inc. a biopharmaceutical company focuses on the discovery development and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development including clinical pre-clinical and research and discovery stages focuses on the development of treatments for multiple therapeutic areas such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518 which is being developed for the treatment of Huntington's disease; bio-e platform such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform including an asset targeting Friedreich ataxia; oncology platform such as Unesbulin; and other multi-platform. PTC Therapeutics Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics Inc. was incorporated in 1998 and is headquartered in South Plainfield New Jersey.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Price Below SMA10D
Midcap (2B - 10B USD)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
30.6%1 month
36.6%3 months
36.7%6 months
58.6%-
-
1.74K
-0.40
0.21
-10.22
2.43
0.81
12.72M
2.70B
2.70B
-
-17.87
-
-12.70
-7.74K
10.82
10.58
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.85
Range1M
8.21
Range3M
9.61
Rel. volume
0.42
Price X volume
10.09M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kymera Therapeutics Inc | KYMR | Biotechnology | 43.06 | 2.83B | -4.31% | n/a | 12.87% |
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.4 | 2.66B | 4.18% | n/a | 0.98% |
Zai Lab Limited | ZLAB | Biotechnology | 26.36 | 2.63B | 2.93% | n/a | 11.88% |
Protagonist Therapeutics Inc | PTGX | Biotechnology | 44.37 | 2.61B | -1.36% | 16.38 | 2.03% |
Geron Corporation | GERN | Biotechnology | 4.32 | 2.60B | -2.70% | n/a | 28.38% |
Verona Pharma plc | VRNA | Biotechnology | 32.01 | 2.60B | 11.49% | n/a | 129.87% |
IDEAYA Biosciences Inc | IDYA | Biotechnology | 29.97 | 2.53B | -5.46% | n/a | 0.20% |
Veracyte Inc | VCYT | Biotechnology | 32.84 | 2.52B | -2.83% | n/a | 1.83% |
ACADIA Pharmaceuticals Inc | ACAD | Biotechnology | 15.1 | 2.50B | -0.20% | 82.58 | 11.16% |
Agios Pharmaceuticals Inc | AGIO | Biotechnology | 41.325 | 2.48B | -1.11% | n/a | 9.78% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -10.22 | 0.76 | Cheaper |
Ent. to Revenue | 2.43 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1,743.27 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 36.67 | 74.67 | Lower Risk |
Debt to Equity | -0.40 | -1.82 | Expensive |
Debt to Assets | 0.21 | 0.26 | Par |
Market Cap | 2.70B | 3.73B | Emerging |